Arthneeti
CB

Concord Biotech

Q1 FY27Pharmaceuticals & Biotechnology

Concord Biotech Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,548
Market cap₹16.4K Cr
P/E57.8
Updated25 Aug 2026
Read5 min read

What the Q1 FY27 call signalled

3 of 3 strong

RevenueRank 2
MarginRank 1
CapexYes

Not discussed on this call: fundraise, order book.

The short version

Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid. Concord Biotech expects growth in FY27 to be better than historical growth rates, supported by business visibility and a robust product pipeline.

From Concord Biotech's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 2
  • Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid.
  • Current capacities show Unit 1 at ~78% utilization and Unit 3 at ~55%-higher than 20-25%, with plans to increase utilization.
  • Future growth relies on oncology and anti-infective products primarily manufactured in Unit 3, with oncology products generating higher revenue despite marginal capacity utilization change.
  • The company expects overall revenue improvement driven by new product launches, increased wallet share, and broader geographic growth.
  • Injectable facility, commercialized last year, is ramping up with sales starting in domestic markets and emerging markets expected next year.
  • CDMO business aims for double-digit contribution from current 1-2%.
  • Brownfield expansion planned when Unit 3 utilization hits 80-85%, with potential capacity additions in fermentation adjacencies like peptides and veterinary products.

Profitability & Margins

See what Concord Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • Concord Biotech is currently not adding capacity for scaling API revenues to INR2,200 crores in 5-6 years, utilizing existing facilities efficiently (Unit 1 at 78%, Unit 2 at 55%, Unit 3 has capacity for pipeline products).
  • Future API capacity expansion will be considered once Unit 3 utilization reaches 80-85%, leveraging available land (only 20-25% used on 160 acres) for brownfield expansion.
  • Potential capex may be required earlier if there’s a need for dedicated fermentation capacities for adjacencies like peptides, veterinary products, etc.
  • The company is exploring both organic and inorganic growth options, including adjacencies in the fermentation space and possible acquisitions.
  • Injectables facility recently commercialized, ramping up sales domestically and targeting emerging markets next year.
  • Cash-rich status (zero debt, INR442 crores cash) supports ongoing and future investments, including three main verticals: CDMO, injectables, and Stellon Biotech.
  • Capital allocation decisions will be driven by utilization levels, market opportunities, and strategic growth prospects.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders in exact terms. However, related insights include: - Concord Biotech has strong business visibility in its pipeline for FY27 and beyond. - The company is working on multiple CDMO projects and expects revenue from this segment to increase from 1-2% to a double-digit contribution. - Several products, including oncology and anti-infectives, are in advanced stages or pipeline that will drive growth. - They continue to engage with innovator customers with a couple of projects progressing well and expected to be in advanced stage or closure by year-end. - The company expects to grow API revenues to INR 2,200 crores in 5-6 years leveraging existing capacity. - They have capacity and capabilities to support revenue growth without immediate new capex, indicating a solid order and demand pipeline. No exact order book value or pending order figures were disclosed.

Concord Biotech — Quarterly revenue & net profit

Revenue Net profit
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹278 Cr, net profit ₹68 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Concord Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Concord Biotech Q1 FY27 results?

Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid. Concord Biotech expects growth in FY27 to be better than historical growth rates, supported by business visibility and a robust product pipeline.

What is Concord Biotech share price analysis?

Concord Biotech currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 57.8 with a market cap of ₹16,438 Cr. Investors should review the full earnings analysis for detailed insights.

Is Concord Biotech planning capital expenditure?

Concord Biotech is currently not adding capacity for scaling API revenues to INR2,200 crores in 5-6 years, utilizing existing facilities efficiently (Unit 1 at 78%, Unit 2 at 55%, Unit 3 has capacity for pipeline products).

Keep Concord Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.